Aligos Therapeutics, Inc. (ALGS) Balance Sheet

The steady contraction of the asset base suggests that the company is consuming its capital reserves at a rate that outpaces its ability to replenish them through milestone payments. This trajectory indicates that the business model remains entirely dependent on external financing to maintain its current operational scale.

While the current ratio of 2.56 suggests a superficial level of short-term coverage, the absolute cash balance is insufficient to support extended Phase 2 clinical trials without further capital raises. Investors should monitor the cash burn closely, as the current liquidity profile leaves little room for operational delays or unexpected clinical setbacks.

The reliance on equity rather than debt is a standard, albeit necessary, strategy for a clinical-stage biotech firm. However, the limited debt capacity suggests that the company lacks the flexibility to leverage its balance sheet for non-dilutive funding, further increasing the likelihood of future equity issuance.

The negative trend in retained earnings highlights the persistent challenge of funding high-cost R&D without a commercial product. This erosion of equity quality suggests that shareholders face ongoing dilution risk as the company continues to tap capital markets to offset its structural deficit.